Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Bioatla Inc (BCAB)

Bioatla Inc (BCAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Viatris Announces Appointments of Scott A. Smith and Elisha W. Finney to the Company's Board of Directors

/PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Scott A. Smith and Elisha W. Finney have been appointed as...

BCAB : 1.5900 (+1.27%)
VTRS : 10.17 (-2.12%)
Does BioAtla, Inc. (BCAB) Have the Potential to Rally 114% as Wall Street Analysts Expect?

The mean of analysts' price targets for BioAtla, Inc. (BCAB) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...

BCAB : 1.5900 (+1.27%)
Can BioAtla, Inc. (BCAB) Climb 260% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for BioAtla, Inc. (BCAB) points to a 259.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts...

BCAB : 1.5900 (+1.27%)
Himalaya Therapeutics Announces Highlights of Recent Clinical Progress

/PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization of a novel class of...

BCAB : 1.5900 (+1.27%)
BioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue Estimates

BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of 10.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

BCAB : 1.5900 (+1.27%)
ROIV : 10.69 (-1.11%)
Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011)

/PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization of a novel class of...

BCAB : 1.5900 (+1.27%)
BioAtla, Inc. (BCAB) Reports Q2 Loss, Lags Revenue Estimates

BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of -10% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

BCAB : 1.5900 (+1.27%)
ARDS : 0.0600 (+3.27%)
BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress

Mecbotamab vedotin (BA3011) Phase 2 preliminary observations in Non-Small Cell Lung Carcinoma (NSCLC) supports advancing to the registrational stage of the...

BCAB : 1.5900 (+1.27%)
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 0% and 27.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

RCUS : 16.97 (-0.18%)
BCAB : 1.5900 (+1.27%)
BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of...

BCAB : 1.5900 (+1.27%)

Barchart Exclusives

3 Highest-yielding Tech Stocks to Buy Now
Tech stocks aren't famous for paying dividends. There are, however, a select few that do. Here are the top 3 based on yield. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar